For decades, countless American workers have been unknowingly exposed to harmful levels of benzene in industrial, manufacturing, and transportation settings. Though invisible and odorless at low concentrations, benzene is a potent carcinogen with a well-established link to blood cancers, particularly acute myeloid leukemia (AML). Tragically, AML often develops years after the initial exposure, leaving victims and their families facing a devastating diagnosis with little understanding of how or why it happened.
At Hughes Law Offices, we work with individuals whose lives have been upended by workplace-related toxic exposure. Understanding the science behind AML and its connection to benzene is the first step toward accountability. Below, we outline the nature of AML, the role benzene plays in its development, and what legal options may be available to those affected.
What is Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow. It is also known as:
- Acute myelogenous leukemia
- Acute myeloblastic leukemia
- Acute granulocytic leukemia
- Acute nonlymphocytic leukemia
AML is the most common type of acute leukemia and typically affects adults. This condition attacks myeloid cells—white blood cells in the bone marrow—rendering them unable to mature or effectively fight infection. As these unhealthy cells build up, they crowd out healthy blood cells, interfering with normal blood function and increasing the risk of infections, bleeding, and fatigue.